| Co-Investigator(Kenkyū-buntansha) |
SANO Tsuyoshi 愛知県がんセンター(研究所), 腫瘍病理学部, 研究員 (60303632)
ABE Tetsuya 愛知県がんセンター(研究所), 疫学・予防部, 研究員 (90378092)
NAGINO Masato 名古屋大学, 医学(系)・研究科(研究院), 教授 (20237564)
YOKOYAMA Yukihiro 名古屋大学, 医学部・附属病院, 講師 (80378091)
KOKURYOU Toshio 名古屋大学, 医学(系)・研究科(研究院), 講師 (60378023)
SENGA Takeshi 名古屋大学, 医学部・附属病院, 講師 (80419431)
西尾 秀樹 名古屋大学, 医学部附属病院, 講師 (30345897)
|
|---|
| Budget Amount *help |
¥48,880,000 (Direct Cost: ¥37,600,000、Indirect Cost: ¥11,280,000)
Fiscal Year 2012: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2009: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2008: ¥22,750,000 (Direct Cost: ¥17,500,000、Indirect Cost: ¥5,250,000)
|
|---|
| Research Abstract |
The combination treatment using Nek2 siRNA and S1 suppressed the tumor growth in colorectal cancer model, more efficiently than Nek2 siRNA. The combined treatment of Nek2 siRNA with CDDP was also more effective than the administration of Nek2 siRNA alone. The combination exerted additive growth inhibition. The transmission of Nek2 siRNA to blood was the highest at 15 min and was less than 0.2μM (0.04% of doses). Nek2 siRNA disappeared within 1 h after the administration.
No abnormalities in blood tests were observed. The No Observed Adverse Effect Level (NOAEL：No Observed Adverse Effect Levels) was 3.7 (mg/kg). Based on the data, we decided the Maximum Recommended Starting Dose (MRSD) as 0.0285 (mg/kg).
|
